A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. - Wohlford GF; Buckley LF; Kadariya D; Park T; Chiabrando JG; Carbone S; Mihalick V; Halquist MS; Pearcy A; Austin D; Gelber C; Abbate A; et al. (PloS one, 2021)